Frontlight ResearchEarly access
Active, not recruitingPhase 1
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ
Key facts
- Who runs it
- GC Biopharma Corp
- Where
- South Korea3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 12 people, planned
- Started
- 20 Sept 2022
- Expected to end
- Jun 2027
- Type of study
- Interventional
- Treatments tested
- GC1123
- Record updated
- 15 October 2024
Who can take part
- Age
- 18 months to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patient who has been diagnosed with severe MPS Ⅱ (Hunter syndrome)
- Patient, aged 1.5 years (18 months) to 18 years at the time of the screening
- Patient who has received and tolerated a minimum of 12 weeks of treatment with weekly intravenous treatment, and who has received 80% of the total planned infusions within that time frame
- Patient who is capable of undergoing neurosurgery, which has been confirmed by neurosurgeons and anesthesiologist
- Patient eligible to execute patient evaluation activities during the clinical trial period, as assessed by the investigator
- Patient whose parents or legal representative are willing to participate in this clinical trial and provide written informed consent form
Who cannot take part
- Patient who has received treatment with any investigational drug or device within 30 days prior to study entry
- Patient who have experience of hypersensitivity or anaphylaxis to ingredients of the investigational product at the time of screening
- Patient with a history of bone marrow transplantation or cord blood transplant
- Patient with a history of ventriculoperitoneal shunt or other intracranial surgeries
- Patient with end-stage multiple organ dysfunction syndrome or other severe diseases
- Patient who is exposed to malignant neoplasm
- Patient with a history of bronchotomy/tracheostomy, or patient with acute respiratory disease at the time of screening
- Patient who is ineligible to participate in the clinical trial due to laboratory test results or other reasons, as determined by the investigator
- Patient who has been administered with intrathecal Idursulfase in the past
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug
The group in the trial
- GC1123 30mgTreatment being tested
30 mg of IP will be administered every 28 days for all enrolled patients
Treatment: GC1123
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Open-Label, Phase 1 and Extension Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ Who Have Central Nervous System Involvement and Are Receiving Treatment with Intravenous Drug
- Record updated
- 15 October 2024